Validation of dried blood samples for adalimumab in IBD-patients

Validation of dried blood samples for adalimumab in IBD-patients - DBS validation adalimumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46650

Enrollment

Registered

2018-03-13

Start date

2018-03-22

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age from 18 years, either male of female Diagnosis of IBD Receiving adalimumab therapy

Exclusion criteria

Exclusion criteria: Contra-indication to adalimumab (TBC, severe infections or congestive heart failure)

Design outcomes

Primary

Measure	Time frame
Primary: to investigate feasibility of DBS from finger prick for measuring adalimumab drug levels and antibodies-to-adalimumab compared with the results of venepuncture serum sample measurements.	—

Secondary

Measure	Time frame
To compare levels of albumin and CRP from DBS with the results of venepuncture serum sample measurement and to investigate feasibility of DBS from finger prick at home.	—

Countries

Netherlands

Outcome results